Meridian Bioscience ( ) - 株価, ニュースと分析Nasdaq:VIVO

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

VIVO 株式概要

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.

会社概要

VIVO ファンダメンタル分析
スノーフレーク・スコア
評価	4/6
将来の成長	0/6
過去の実績	1/6
財務の健全性	6/6
配当金	0/6

報酬

当社が推定した公正価値より25.5%で取引されている

リスク分析

利益率(12.7%)は昨年より低い(22.5%)

財務結果に影響を与える大きな一時的項目

Meridian Bioscience, Inc. 競合他社

STAAR Surgical

NasdaqGM:STAA

US$1.8b

UFP Technologies

NasdaqCM:UFPT

US$2.5b

Avanos Medical

NYSE:AVNS

US$1.0b

Embecta

NasdaqGS:EMBC

US$817.1m

価格と性能

の歴代最高値、変動、値下がりまとめMeridian Bioscience
過去の株価
現在の株価	US$33.97
52週高値	US$34.38
52週安値	US$21.09
ベータ	0.23
11ヶ月の変化	2.29%
3ヶ月変化	6.02%
1年変化	54.34%
33年間の変化	295.23%
5年間の変化	128.75%
IPOからの変化	6,030.20%

Recent updates

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Aug 05

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Jun 09

Meridian Bioscience: Deceptively Priced

Mar 14

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Feb 03

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Jul 19

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Jul 08

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

May 10

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

May 08

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Mar 31

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Mar 11

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Feb 24

Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Feb 09

Meridian expands production capacity for COVID-19 tests with NIH funding

Feb 03

Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Jan 27

株主還元

	VIVO	US Medical Equipment	US 市場
7D	0.06%	-0.6%	0.9%
1Y	54.3%	20.8%	32.3%

業界別リターン: VIVO過去 1 年間で1.7 % の収益を上げたUS Medical Equipment業界を上回りました。

リターン対市場: VIVO過去 1 年間で21.8 % の収益を上げたUS市場を上回りました。

価格変動

Is VIVO's price volatile compared to industry and market?
VIVO volatility
VIVO Average Weekly Movement	2.3%
Medical Equipment Industry Average Movement	8.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

安定した株価: VIVO過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: VIVOの週次ボラティリティ ( 2% ) は過去 1 年間安定しています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1976	704	Jack Kenny	www.meridianbioscience.com

Meridian Bioscience, Inc. 基礎のまとめ

Meridian Bioscience の収益と売上を時価総額と比較するとどうか。
VIVO 基礎統計学
時価総額	US$1.49b
収益（TTM）	US$42.46m
売上高(TTM)	US$333.02m

35.2x

PER（株価収益率

4.5x

P/Sレシオ

VIVO は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
VIVO 損益計算書（TTM）
収益	US$333.02m
売上原価	US$144.66m
売上総利益	US$188.36m
その他の費用	US$145.90m
収益	US$42.46m

直近の収益報告

Sep 30, 2022

次回決算日

該当なし

一株当たり利益（EPS）	0.96
グロス・マージン	56.56%
純利益率	12.75%
有利子負債／自己資本比率	6.8%

VIVO の長期的なパフォーマンスは？

過去の実績と比較を見る

VIVO 株式概要

報酬

リスク分析

Meridian Bioscience, Inc. 競合他社

NasdaqGM:STAA

US$1.8b

NasdaqCM:UFPT

US$2.5b

NYSE:AVNS

US$1.0b

NasdaqGS:EMBC

US$817.1m

価格と性能

最新ニュース

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in Vitro Diagnostic Manufacturers

Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Recent updates

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in Vitro Diagnostic Manufacturers

Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Independent Director exercised options to buy US$285k worth of stock.

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$34.00

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Consensus EPS estimates fall by 31%

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience: High-Probability Merger Arbitrage

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience downgraded at William Blair on $1.53B acquisition

Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Bioscience: Correctly Valued

President exercised options and sold US$1.1m worth of stock

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience: Deceptively Priced

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

Price target increased to US$30.00

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Key Executive exercised options to buy US$157k worth of stock.

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Price target decreased to US$27.00

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Price target decreased to US$30.50

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Consensus forecasts updated

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021